Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00663767 · ClinicalTrials.gov registry record · Phase 2

A Study of ARRY-371797 in Subjects Undergoing Third Molar Extraction

A Phase 2 study of Dental Pain, sponsored by Pfizer.

Completed
Registry status
Phase 2
Development phase
250
Enrollment target
2
Study locations

NCT00663767: Completed Phase 2 study of Dental Pain, sponsored by Pfizer.

NCT00663767 is a Phase 2 study of Dental Pain that has completed, run by Pfizer. The registered enrollment target is 250 participants, above the 204-participant average among 6 other Dental Pain trials with a reported enrollment target (23% higher). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00663767, a Phase 2 study of Dental Pain, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 2
Development phase
250 participants
Enrollment target
2
Study locations

Study Summary

This is a Phase 2 study designed to test the ability of investigational study drug ARRY-371797 to reduce pain in a postoperative pain model (third molar extraction), and to further evaluate the drug's safety. Approximately 250 subjects from the US will be enrolled in this study.

Conditions Studied

Interventions

  • DRUG ARRY-371797, p38 inhibitor; oral
  • DRUG Placebo; oral
  • DRUG Celecoxib, COX-2 inhibitor; oral

Study Locations (2)

Texas

  • PPD Phase I Clinic - Austin

Utah

  • Lifetree Clinical Research - Salt Lake City

Trial Details

FieldValue
Enrollment Target 250 participants
Start Date 2008-04-07
Est. Completion 2008-06-20
Phase Phase 2
Pfizer

1,845 total trials

What the finished NCT00663767 record still lists

NCT00663767 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, above the 204-participant average among 6 other Dental Pain trials with a reported enrollment target (23% higher).

The record links to 1 condition, with Dental Pain appearing as the primary indexed condition, and to 3 interventions - of which ARRY-371797, p38 inhibitor; oral is the first listed.

NCT00663767 reports a single indexed study location in Texas, Utah.

Frequently Asked Questions

What is clinical trial NCT00663767 about?

NCT00663767 is a clinical study titled "A Study of ARRY-371797 in Subjects Undergoing Third Molar Extraction". This is a Phase 2 study designed to test the ability of investigational study drug ARRY-371797 to reduce pain in a postoperative pain model (third molar extraction), and to further evaluate the drug's safety. Approximately 250 subjects from the US will be enrolled in this study.

What is the current status of trial NCT00663767?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 250 participants. The study started on 2008-04-07. Estimated completion is 2008-06-20.

What conditions does trial NCT00663767 study?

This clinical trial studies the following conditions: Dental Pain.

What interventions are being tested in trial NCT00663767?

The interventions under investigation include: ARRY-371797, p38 inhibitor; oral (DRUG), Placebo; oral (DRUG), Celecoxib, COX-2 inhibitor; oral (DRUG).

Who is sponsoring clinical trial NCT00663767?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00663767 being conducted?

This trial has 2 study locations across Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Dental Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00483249 · 250 participants · NA

    Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm

  • NCT00777712 · 250 participants

    Mechanisms Underlying Impaired Diabetic Wound Healing

  • NCT01451502 · 250 participants · NA

    Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units

  • NCT01771718 · 250 participants

    Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00663767, the US trial registry maintained by the National Library of Medicine. NCT00663767 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.